% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Albert:1024594,
      author       = {Albert, Nathalie L and Galldiks, Norbert and Ellingson,
                      Benjamin M and van den Bent, Martin J and Chang, Susan M and
                      Cicone, Francesco and de Groot, John and Koh, Eng-Siew and
                      Law, Ian and Le Rhun, Emilie and Mair, Maximilian J and
                      Minniti, Giuseppe and Rudà, Roberta and Scott, Andrew M and
                      Short, Susan C and Smits, Marion and Suchorska, Bogdana and
                      Tolboom, Nelleke and Traub-Weidinger, Tatjana and Tonn,
                      Joerg-Christian and Verger, Antoine and Weller, Michael and
                      Wen, Patrick Y and Preusser, Matthias},
      title        = {{PET}-based response assessment criteria for diffuse
                      gliomas ({PET} {RANO} 1.0): a report of the {RANO} group},
      journal      = {The lancet / Oncology},
      volume       = {25},
      number       = {1},
      issn         = {1470-2045},
      address      = {London},
      publisher    = {The Lancet Publ. Group},
      reportid     = {FZJ-2024-02268},
      pages        = {e29 - e41},
      year         = {2024},
      abstract     = {Response Assessment in Neuro-Oncology (RANO) response
                      criteria have been established and were updated in 2023 for
                      MRI-based response evaluation of diffuse gliomas in clinical
                      trials. In addition, PET-based imaging with amino acid
                      tracers is increasingly considered for disease monitoring in
                      both clinical practice and clinical trials. So far, a
                      standardised framework defining timepoints for baseline and
                      follow-up investigations and response evaluation criteria
                      for PET imaging of diffuse gliomas has not been established.
                      Therefore, in this Policy Review, we propose a set of
                      criteria for response assessment based on amino acid PET
                      imaging in clinical trials enrolling participants with
                      diffuse gliomas as defined in the 2021 WHO classification of
                      tumours of the central nervous system. These proposed PET
                      RANO criteria provide a conceptual framework that
                      facilitates the structured implementation of PET imaging
                      into clinical research and, ultimately, clinical routine. To
                      this end, the PET RANO 1.0 criteria are intended to
                      encourage specific investigations of amino acid PET imaging
                      of gliomas},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5252},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {38181810},
      UT           = {WOS:001157190300001},
      doi          = {10.1016/S1470-2045(23)00525-9},
      url          = {https://juser.fz-juelich.de/record/1024594},
}